JP2008540405A5 - - Google Patents

Download PDF

Info

Publication number
JP2008540405A5
JP2008540405A5 JP2008509964A JP2008509964A JP2008540405A5 JP 2008540405 A5 JP2008540405 A5 JP 2008540405A5 JP 2008509964 A JP2008509964 A JP 2008509964A JP 2008509964 A JP2008509964 A JP 2008509964A JP 2008540405 A5 JP2008540405 A5 JP 2008540405A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
eslicarbazepine
daily dose
once
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008509964A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008540405A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/PT2005/000006 external-priority patent/WO2006121363A1/en
Publication of JP2008540405A publication Critical patent/JP2008540405A/ja
Publication of JP2008540405A5 publication Critical patent/JP2008540405A5/ja
Pending legal-status Critical Current

Links

JP2008509964A 2005-05-06 2005-05-06 酢酸エスリカルバゼピン及び使用方法 Pending JP2008540405A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/PT2005/000006 WO2006121363A1 (en) 2005-05-06 2005-05-06 Eslicarbazepine acetate and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013133842A Division JP2013237676A (ja) 2013-06-26 2013-06-26 酢酸エスリカルバゼピン及び使用方法

Publications (2)

Publication Number Publication Date
JP2008540405A JP2008540405A (ja) 2008-11-20
JP2008540405A5 true JP2008540405A5 (enExample) 2012-07-12

Family

ID=35464075

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008509964A Pending JP2008540405A (ja) 2005-05-06 2005-05-06 酢酸エスリカルバゼピン及び使用方法

Country Status (8)

Country Link
EP (6) EP2380573B1 (enExample)
JP (1) JP2008540405A (enExample)
KR (1) KR101236227B1 (enExample)
CN (1) CN101217959A (enExample)
ES (2) ES2534514T3 (enExample)
PT (2) PT2380573E (enExample)
RU (1) RU2010154008A (enExample)
WO (1) WO2006121363A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
GB0700773D0 (en) * 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
CN102612359A (zh) 2009-09-10 2012-07-25 拜欧波尔特拉及正大有限公司 醋酸艾司利卡西平的口服混悬剂制剂
TR201008460A1 (tr) * 2010-10-15 2012-05-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Eslikarbazepinin saşe formülasyonları.
EP2747770A1 (en) 2011-08-26 2014-07-02 BIAL - Portela & Cª S.A. Treatments involving eslicarbazepine acetate or eslicarbazepine
US9814723B2 (en) 2013-02-23 2017-11-14 Lixin Zhang Compositions and methods for prophylaxis and therapy for Meniere's disease
US20140243342A1 (en) * 2013-02-23 2014-08-28 Lixin Zhang Compositions and methods for prophylaxis and therapy for menieres disease
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
GB201306095D0 (en) * 2013-04-04 2013-05-22 Bial Portela & Ca Sa New treatments

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT101732B (pt) * 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
US6296873B1 (en) 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
IL161700A0 (en) * 2001-11-12 2004-09-27 Novartis Ag Monohydroxycarbamazepine for use in the preparation of a medicament for the treatment of affective and attention disorder and neuropathic pain
CA2494660A1 (en) * 2002-08-06 2004-02-19 Novartis Ag Use of carboxamides for the treatment of tinnitus
US20040038874A1 (en) * 2002-08-22 2004-02-26 Osemwota Omoigui Method of treatment of persistent pain
GB0303615D0 (en) * 2003-02-17 2003-03-19 Novartis Ag Use of organic compounds
BRPI0407569A (pt) * 2003-02-17 2006-02-14 Novartis Ag uso de s-10-hidróxi-10, 11-diidro-carbamazepina para o tratamento de ansiendade e distúrbios bipolares
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
GB2401605A (en) * 2003-05-12 2004-11-17 Portela & Ca Sa Method for racemisation of (S)-(+)- and (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide and optically enriched mixtures thereof
AR048672A1 (es) * 2004-03-22 2006-05-17 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina
PE20051156A1 (es) * 2004-03-22 2006-02-13 Novartis Ag Formulaciones de matriz orales que comprenden licarbazepina
MX366496B (es) * 2005-05-06 2019-07-11 Bial Portela & Ca Sa Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso.

Similar Documents

Publication Publication Date Title
JP2019048843A5 (enExample)
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer&#39;s disease
JP2006504795A5 (enExample)
JP2024075655A5 (ja) 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用
JP2000515486A (ja) アダマンタン誘導体の内耳炎治療向け使用
JP2009514874A5 (enExample)
JP2005515966A5 (enExample)
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
JP2020514282A5 (enExample)
JP2018507243A5 (enExample)
RU2003100507A (ru) Фармацевтические композиции
WO2009022821A3 (en) Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same
JP2017533211A5 (enExample)
JP2010065060A (ja) 心不全処置のための複合治療
JP2021001221A (ja) 精神障害の治療における使用のためのイロペリドン代謝物
RU2494736C2 (ru) Комбинация, включающая паклитаксел, для лечения рака яичников
RU2005133665A (ru) Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств
JP5677856B2 (ja) 医薬組成物
CA2476939A1 (en) Pharmaceutical combinations of cox-2 inhibitors and opiates
IL272834B1 (en) Compositions of amantadine, their preparation, and methods of use
EP1154766B1 (de) Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln, zur behandlung von erkrankungen bei mensch und tier, welche durch die hemmung der aktivierung von nf-kappa b therapeutisch beeinflusst werden können
JP2019531286A5 (enExample)
CA2727722A1 (en) Use of dihydroimidazolones for the treatment of anxiety in dogs
KR20080108515A (ko) 고혈압의 치료를 위한 레닌 억제제
AU2004268381B2 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep